Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients ...

A diabetes drug may beat costly shots for patients with a rare genetic condition, according to a Rutgers Health study.

The actor said he lost 40 pounds taking GLP-1 medication before a negative side effect necessitated a change to a different ...

U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

An experimental drug called amycretin showed signs it could be more potent than Eli Lilly’s rival Zepbound, though analysts ...

The Danish pharmaceutical giant reported positive early-stage results for its once weekly amycretin obesity drug.

Demand for weight-loss medications sold under brand names such as Ozempic and Wegovy continues to surge, with a recent study ...

We recently compiled a list of the 10 Best Stocks to Invest in According to Billionaire Cliff Asness. In this article, we are ...

After Novo Nordisk (NVO) reported results from its Phase 3b STEP UP trial, which showed that adults with obesity achieved a 20.7% weight loss ...

Argus lowered the firm’s price target on Novo Nordisk (NVO) to $110 from $140 but keeps a Buy rating on the shares and contends that the ...

Best of luck, and do keep in touch. … When Eli Lilly last year started offering lower-priced vials of its blockbuster obesity drug Zepbound, which were previously sold in injectable pens ...